Zentalis Pharmaceuticals Inc (NAS:ZNTL)
$ 11.65 0.21 (1.84%) Market Cap: 827.30 Mil Enterprise Value: 366.02 Mil PE Ratio: 0 PB Ratio: 1.80 GF Score: 36/100

Zentalis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 02:35PM GMT
Release Date Price: $24.72 (-6.54%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here, and it's my pleasure to introduce Kim Blackwell, CEO from Zentalis Pharmaceuticals. Just a reminder, format for today is a fireside chat. But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, right in the Q&A. Kim, thanks for joining us today.

Kimberly Lynn Blackwell
Zentalis Pharmaceuticals, Inc. - CEO & Director

Thanks for having me.

Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

Makes sense. Almost out of time. So, it

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot